

Veklury® (remdesivir)

When requesting Veklury® (remdesivir), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved Indication

Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in patients 12 years of age and older with mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

Approved Off-label Compendial Indication

Veklury is approved for the treatment of coronavirus disease 2019 (COVID-19) in patients < 12 years of age with mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

Coverage Guidelines

Coronavirus Disease 2019 (COVID-19)

The individual must meet **all** of the following criteria for authorization:

- Weighs ≥ 3.5 kg; AND
- Has mild-to-moderate COVID-19 confirmed with positive results of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing; AND

Is at high risk of progression to severe COVID-19, including hospitalization or death.

Approval duration: 3 days (one treatment course)

Dosing Recommendations

Patients weighing ≥ 40 kg: Administer a single loading dose of 200 mg on Day 1 via intravenous infusion, followed by once-daily maintenance doses of 100 mg for a total treatment duration of 3 days.

Patients weighing ≥ 3.5 kg and < 40 kg: Administer a single loading dose of 5 mg/kg on Day 1 via intravenous infusion, followed by once-daily maintenance doses of 2.5 mg/kg for a total treatment duration of 3 days.

References

1. Veklury® [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; January 2022.
2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed March 9, 2022.